Latest Conference Articles

Kimberly Westrich on Incentivizing Value-Based Care in Benefit Design and Reimbursement Strategies

Kimberly Westrich on Incentivizing Value-Based Care in Benefit Design and Reimbursement Strategies

November 28th 2021, 2:00pm

National Alliance of Healthcare Purchaser Coalitions

Kimberly Westrich, MA, vice president of health services research at the National Pharmaceutical Council, discusses the shift to a value-based system from a fee-for-service one and how the health care system can incentivize high-value care.

Daniel Wolfson Discusses Mistrust, Quality Implications in the Health Care System

Daniel Wolfson Discusses Mistrust, Quality Implications in the Health Care System

November 24th 2021, 12:00am

National Alliance of Healthcare Purchaser Coalitions

Daniel Wolfson, executive vice president and chief operating officer of the ABIM Foundation, speaks on factors influencing mistrust of the health care system and efforts to improve quality care.

Bentracimab Offers “Immediate, Sustained” Reversal of Antiplatelet Drug Ticagrelor in Nearly All Cases in REVERSE-IT

Bentracimab Offers “Immediate, Sustained” Reversal of Antiplatelet Drug Ticagrelor in Nearly All Cases in REVERSE-IT

November 16th 2021, 2:40pm

American Heart Association Scientific Sessions

Bleeding is a risk with all antiplatelet drugs, whose effects pose a problem when patients need surgery or suffer a traumatic injury. A fast-acting reversal agent would make the drug safer to use.

Dr Deepak Bhatt Explains Interim Results of REVERSE-IT Trial

Dr Deepak Bhatt Explains Interim Results of REVERSE-IT Trial

November 16th 2021, 1:00am

American Heart Association Scientific Sessions

Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital Heart & Vascular Center and professor of medicine at Harvard Medical School, explains the interim findings of the REVERSE-IT trial that were presented at the 2021 AHA Scientific Sessions.

New Data Presented for Finerenone, Vericiguat, and SGLT2 Inhibitors at HF Session

New Data Presented for Finerenone, Vericiguat, and SGLT2 Inhibitors at HF Session

November 16th 2021, 12:00am

American Heart Association Scientific Sessions

A panel Monday at the 2021 American Heart Association Scientific Sessions featured new results for several heart failure (HF) therapeutics, including finerenone and empagliflozin, as well as cost-effectiveness data for vericiguat.

Dr Derek Chew on the VICTORIA Trial and the Cost-effectiveness of Vericiguat

Dr Derek Chew on the VICTORIA Trial and the Cost-effectiveness of Vericiguat

November 15th 2021, 11:00pm

American Heart Association Scientific Sessions

The VICTORIA study found vericiguat to be more cost-effective than placebo when using current societal benchmarks for health care value in the United States. Derek Chew, MD, now an assistant professor at the University of Calgary, conducted economic evaluations for the VICTORIA trial while with the Duke Clinical Research Institute. Results were presented at the 2021 AHA Scientific Sessions. Here, he explains why vericiguat is more cost-effective for patients with heart failure with reduced ejection fraction.

Teprotumumab Benefits Patients With Mild Inflammation and Real-world Adherence Remains High

Teprotumumab Benefits Patients With Mild Inflammation and Real-world Adherence Remains High

November 15th 2021, 8:45pm

AAO: American Academy of Ophthalmology

Posters presented at the American Academy of Ophthalmology 2021 annual meeting showed that even patients with mild inflammation with their thyroid eye disease benefitted from teprotumumab and that real-world adherence was consistent with the pivotal clinical trials.

Teprotumumab, Enhanced Monofocal IOLs Among Hot Topics at AAO 2021

Teprotumumab, Enhanced Monofocal IOLs Among Hot Topics at AAO 2021

November 15th 2021, 6:35pm

AAO: American Academy of Ophthalmology

Among many presentations during a hot topics session at the American Academy of Ophthalmology 2021 annual meeting, speakers discussed the first FDA approved therapy for thyroid eye disease and the latest in enhanced monofocal intraocular lenses (IOLs).

Dr David Ramsey Describes the Impact of Telehealth on Completed Eye Examinations for Diabetic Retinopathy

Dr David Ramsey Describes the Impact of Telehealth on Completed Eye Examinations for Diabetic Retinopathy

November 15th 2021, 5:49pm

AAO: American Academy of Ophthalmology

David Ramsey, MD, PhD, MPH, explains findings from a study on telehealth use among patients with diabetes in Massachusetts.

Patient Voices Highlight Urgency of Achieving Health Equity During AHA Session

Patient Voices Highlight Urgency of Achieving Health Equity During AHA Session

November 15th 2021, 3:48am

American Heart Association Scientific Sessions

A wide-ranging discussion sought to bring greater urgency to achieving health equity during the 2021 American Heart Association (AHA) Scientific Sessions.